Development of Second-Generation Phenoxyethylpiperidines as Potent Sigma-1 Receptor Agonists with Neuroprotective Potential for Alzheimer’s Disease

to assess hyperlocomotion reduction. Seven hit compounds were selected for the BiP-S1R dissociation as a measure of their agonist activity, followed by the preclinical evaluation of their activity against Alzheimer's Disease (AD) in mice. These phenoxyethylpiperidines demonstrated to potently prevent AD-like amnesia without toxicity, appearing as promising agents for further preclinical studies against neurodegeneration.